据了解，东脑智合汇聚了半导体和神经科学领域的顶尖人才。创始人龚轶先生同时担任东微半导（股票 代码：688261.SH）董事长，在半导体领域积累了深厚的技术功底。东脑智合引入国际上经验丰富的生 物传感器芯片开发资深团队，在芯片底层技术上实现超低功耗高通量脑专用芯片和系统的定义和开发。 据悉，12月初，2025年全国脑机接口大会将在脑智天地集聚区举办，届时，全球的脑机接口专家和前沿 科技人才都将汇聚于此，共同畅想脑机接口未来产业在中国的发展和应用。 电极技术核心技术团队由中国科学院半导体所研究员、国科大岗位教授裴为华领衔。裴为华致力于神经 接口技术研究20余年，现担任中国脑机接口产业联盟硬件组副主席。 （文章来源：证券时报网） 东脑智合表示，作为一家专注于侵入式脑机接口技术研发的创新企业，公司以全球独创的液压驱动柔性 神经触手电极技术为核心，致力于发展科研级和医疗级侵入式脑机接口全栈式核心技术，目标成为全球 顶尖的脑机接口公司。 近日，上海东脑智合技术有限公司（以下简称"东脑智合"）完成注册，正式落地全国首个以脑机接口技 术发展为目标的特色产业集聚区——上海脑机接口未来产业集聚区（脑智天地）。 "十二五 "以来， ...

在 2025年11月于美国圣地亚哥举行的 第十二届国际神经工程大会 （ IEEE EMBS Neural Engineering Conference, NER 2025 ）上，中国 脑科学 创新企业 深圳市 应和脑科学 有限公司 （ Amygdala Neuro ，下文简称 "应和脑科学" ）正式报告 其自主研发的 介入脑机接口 ——颅内 血管支架电极 脑机 系统在大型动物模型中实现 长期植入 的关键成果 。该研究题为 《 Evaluation of a Novel Endovascular Electrode Array for Long-Term Cortical Recording and Stimulation 》 ，标志着应 和 脑科学介入脑机接口 在脑机接口（ BCI）核心技术领域取得实质性突破 ， 该工作不仅验证了 介入脑机接口 架构的长期可 行性，也为未来 BCI系统的临床转化提供了新路径。 本研究的核心在于首次在大型动物模型中验证了一种机械架构的颅内血管支架电极阵列具备近半年的双模态（ 记录 +刺激 ） 功能稳定性。相较于现有技术，其机械编织结构成本更低、工艺更灵活，有望加速国产化 BCI ...

"海淀既是国家人工智能发展高地，也是'AI+脑机数据'策源地。"海淀区委副书记、区政府党组书记许 心超表示，海淀区作为北京市医药健康产业核心承载区，形成了从研发到转化、从生产到应用的完整产 业链条，呈现出"基础学科全面、临床资源聚集、人才梯队完备"的独特优势，为"AI+脑机"技术的研发 与落地提供了肥沃土壤。 清华大学党委副书记、校长李路明表示，清华大学将不断加强脑机接口核心技术攻关，推进基础研究与 临床医学合作，围绕"AI+脑机数据"，持续加强创新平台建设，大力培养创新人才，努力产出更多标志 性、引领性的创新成果。 此外，信通院牵头，联合国内优势高校院所、医疗机构及创新企业，以标准、平台、生态为牵引，发起 筹备中关村脑机接口产业协会，将聚焦服务脑机接口技术协同攻关、成果转化落地、标准体系建设、专 业人才培养和产业创新生态搭建，推动产业链上下游协同发展。脑科学多模态通用基础大模型、脑疾病 AI精准诊疗系统等六项脑机接口创新成果集中亮相，展示北京在脑机接口领域从单点技术到系统集成 的自主创新能力。 新京报讯(记者吴为)北京市"AI+脑机"产业创新工作推进会11月21日在海淀举行。推进会以"脑智融合.慧 聚北京" ...

Core Viewpoint - The article highlights the advancements in brain-computer interface technology by Qiangnao Technology, led by founder Han Bicheng, emphasizing its practical applications in improving the quality of life for individuals with disabilities [1][18]. Company Background - Qiangnao Technology, founded in 2015, focuses on developing brain-computer interfaces, aiming to bridge the gap between neuroscience research and practical applications that can bring about positive changes in people's lives [3][4]. - The company name "BrainCo" is a direct abbreviation of "brain computer interface," clearly stating its core mission [4]. Product Development - The team dedicated seven to eight years to develop a bionic hand, which is crucial for individuals with disabilities, as the hand is the most complex part controlled by the brain [8][9]. - The first generation of the bionic hand weighs approximately 500 grams, while the second generation has been reduced to over 300 grams, making it more user-friendly [11]. User Experience - User testimonials, such as that of Ni Mincheng, who has been using the bionic hand since 2019, demonstrate significant improvements in daily life, including the ability to perform tasks like cooking and writing [12][15][20]. - The technology allows for intuitive control, enabling users to operate the hand as they think, with capabilities for simultaneous and independent finger movements [13][15]. Market Position and Strategy - Qiangnao Technology has established itself as a leading player in the industry, recognized among the "Six Little Dragons of Hangzhou," which includes companies with over ten years of experience [18]. - The company emphasizes continuous optimization of user experience and adapting technology to meet the diverse needs of users, including different limb conditions and environmental factors [20][23]. Competitive Landscape - Han Bicheng expresses a strong sense of urgency regarding competition, stating that the company must innovate and improve faster than others in the field [21][22]. - The focus remains on creating practical solutions rather than mere demonstrations, with a commitment to addressing real user needs [22][23].

Core Insights - The Percept™ RC, the world's first rechargeable and sensing closed-loop brain stimulator, has commenced clinical applications in major hospitals across Beijing, Anhui, and Shanxi as of November 2025 [1][4] - Developed by Medtronic, the device integrates artificial intelligence and brain-machine interface technology, and is approved by the Chinese National Medical Products Administration, the US FDA, and the EU CE for treating complex neurological disorders such as Parkinson's disease and drug-resistant epilepsy [3][4] - The device has been recognized as one of TIME magazine's "Best Inventions of 2025" and has been featured prominently at the China International Import Expo [3][4] Clinical Application - The clinical application of Percept™ RC marks a significant breakthrough in brain stimulator therapy, advancing the use of brain-machine interface technology for treating neurological diseases in China [4] - The device offers a more intelligent, precise, and comfortable treatment option for patients, enhancing the overall treatment experience [4][8] Technological Advancements - Compared to traditional brain stimulators, Percept™ RC provides real-time sensing and analysis of brain activity, allowing for personalized and precise treatment tailored to the patient's condition [8] - It is the smallest and lightest brain stimulator globally, being 37% smaller than traditional models, which improves patient comfort [8] - The device features an open lifespan battery technology and is fully compatible with 3.0T and 1.5T MRI scans, ensuring patient safety and access to future medical imaging [8] Historical Context - Deep brain stimulation (DBS), commonly known as "brain pacemaker," has been recognized as the preferred surgical treatment for Parkinson's disease since its first successful operation in 1987 [5] - The therapy has been clinically applied for over 35 years globally, with its introduction to China occurring in 1999 [5]

公司脑机业务预计于2026年3月推出原型机。此外公司与国际非侵入式脑机接口技术巨头NeuroSky（神 念科技）达成战略合作，双方将成立合资企业，脑机接口与多模态生物识别技术的深度融合进入新阶 段。双方将共同构建"芯片+情绪云+产业生态"的创新架构，加速脑机接口技术的全球战略布局。 格隆汇11月18日丨熵基科技(301330.SZ)接受机构调研时表示，公司脑机技术聚焦教育、医疗、养老三 大核心应用场景，运用AI驱动的多模态数据融合技术，围绕分析诊断、检测辅助康复、治疗三大方向 开展产品研发。在智慧教育领域，公司通过开发脑机接口互动游戏等趣味化形式，将技术与教育场景深 度融合，针对性培养青少年的专注力，推动脑机技术在智慧教育领域的落地应用。 ...

国产"芯"突破创造奇迹，偏瘫患者能自主喝水了。11月14日，长江日报记者从华中科技 大学同济医学院附属协和医院（以下简称协和医院）获悉，该院完成全国产自主研发脑机接 口芯片首例临床植入手术，并成功采集到患者大脑中感觉运动区域的神经信号。目前，患者 接受了一个多月的康复训练后，几乎丧失功能的右手已能完成一些精细动作，运动功能显著 改善。 两年前，河南患者刘先生因脑梗塞导致整个右侧肢体瘫痪，尽管尝试了为期一个月的无 创脑机接口训练，但其手部功能并未明显改善。协和医院脑机接口专家团队全面评估病情， 与家属沟通后，决定实施脑机接口芯片植入手术。 9月22日，协和医院神经外科主任姜晓兵教授团队成功将全国产脑机接口芯片植入到患 者脑部。姜晓兵介绍，手术采用"武汉研发"高端脑机接口技术，将芯片精准植入患者的颅 内，既保证了较高的信息采集质量，又能最大限度降低手术风险。 术后，当患者用"意念"驱动手指伸展或抓握时，系统立即控制气动手套完成相应动作， 进而促进部分神经恢复，加速肢体功能重建。 目前，刘先生恢复良好，无并发症，植入芯片性能稳定，神经信号解码准确率持续保持 在95％以上。 一个多月来，医护人员指导刘先生进行系统康复 ...

Core Insights - The article highlights a significant milestone in China's brain-computer interface (BCI) technology, showcasing the first semi-invasive BCI implantation surgery in Western China, which was documented by the media for the first time [1][3][6] - The documentary "AI China" aims to explore the intersection of advanced technology and human experiences, focusing on themes of love, growth, death, rebirth, dreams, and transcendence [3][4] - The advancements in BCI technology are positioned against the backdrop of global competition, particularly with companies like Neuralink, which has ambitious plans for visual restoration and brain function repair by 2026 and 2029 respectively [3][4] Industry Developments - The BCI field integrates multiple disciplines, including brain science, neurology, materials science, psychology, and computer science, reflecting its complexity and the collaborative efforts required for advancements [3][4] - Researchers in China, such as Professor Hongbo from Tsinghua University, are developing innovative BCI devices that are minimally invasive and capable of accurately decoding patients' motor intentions [4][12] - The documentary captures the ongoing clinical trials and the personal stories of patients, emphasizing the human aspect of technological advancements and the quest for dignity and freedom through science [5][9][10] Patient Experiences - The article details the experiences of patients like Lao Yang and Xiao Dong, who have undergone BCI surgeries and are engaged in rigorous rehabilitation, highlighting the emotional and physical challenges they face [5][9][10] - Lao Yang, the first participant in a semi-invasive BCI trial, has shown significant recovery, regaining some motor functions and emotional connections through the technology [5][10] - Xiao Dong's journey illustrates the struggles of a patient from a rural background, emphasizing the societal implications of BCI technology and the hope it brings to those with severe disabilities [8][9] Research and Innovation - The article emphasizes the importance of focusing on affordable and effective health solutions in the context of BCI technology, as articulated by experts like Academician Pu Muming [11][12] - The documentary showcases the dedication of researchers and medical professionals who are pioneering BCI technology in China, aiming to make significant contributions to the treatment of neurological disorders [12][14] - The narrative underscores the need for a balance between technological advancement and humanistic storytelling, aiming to present a comprehensive view of the impact of BCI on patients' lives [4][13]

核心观点 简评 Q3 业绩符合预期，海外市场高增长，利润波动与费用增加有关2025 年前三季度，公司营收、归母净利 润、扣非归母净利润分别为8.08、1.80、1.40 亿元，分别同比增长34.24%、43.87%和63.41%；2025Q3 营收、归母净利润和扣非归母净利润分别为2.64、0.49 和0.40 亿元，分别同比增长20.22%、48.61%和 112.64%，环比增速分别为-5.09%、-18.09%、+3.21%，业绩符合预期。25Q3 利润增速高于收入增速， 主要系毛利率提升和费用率下降所致。 Q3 业绩符合预期，海外市场高增长，利润波动与费用增加有关。 展望Q4，公司收入有望加速增长，利润在低基数下有望实现高增长。 公司无降噪棉呼吸机新品自7 月开始已经批量进入美国市场， 四季度有望加速放量；在欧洲市场，公司 已基本完成云平台建设，通过本土化运营策略，公司产品开始进入主流医保市场；在国内市场，公司9 月底启动线上经销向直销模式切换，第三季度处于模式转换初期，预计第四季度新模式开始增厚业绩。 事件 公司发布2025 年三季报 2025 年前三季度，公司营收、归母净利润、扣非归母净利润分别为 ...

Core Insights - A new brain-machine interface chip thinner than a human hair has been developed, showing potential for treating neurological diseases such as Parkinson's and epilepsy, and opening new avenues in biomedical engineering [1][2] Group 1: Technology Development - The MIT Media Lab team has created a brain-machine interface chip using a novel organic semiconductor material, which is attached to immune cells and delivered via intravenous injection [2] - This technology allows for non-invasive implantation of the device into the brain, overcoming the limitations of current invasive methods that require surgical procedures [1][2] Group 2: Clinical Application and Market Potential - The research is in the early stages of transitioning from basic research to clinical application, with successful in vivo experiments conducted on live animals [1][2] - The recent approval of a wireless implanted brain-machine interface system by Shanghai Ladder Medical Technology Co., Ltd. marks a significant step for invasive brain-machine interface technology in China, facilitating faster market entry [2][3] Group 3: Future Implications - The brain-machine interface technology has the potential to significantly benefit patients with paralysis, speech impairments, and other neurological disorders, possibly enabling quicker recovery for those who have lost consciousness [3] - Collaboration across multiple disciplines, including materials science, artificial intelligence, and medicine, is essential for the advancement of brain-machine interface technology [3]